Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche’s Tecentriq recommended for EU approval to treat lung cancer form

The European Medicine Agency’s Committee for Medicinal Products for Human Use recommended EU approval of Roche’s cancer immunotherapy Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer, the Basel, Switzerland-based company said.

Read More »

FDA approves Roche’s small cell lung cancer treatment

Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.

Read More »

Roche’s lung cancer combo treatment wins FDA approval

Roche Holding AG’s Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.

Read More »

Roche’s Tecentriq wins speedy U.S. FDA review for small cell lung cancer

Swiss group Roche Holding AG said the company’s Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals’ revenues.

Read More »

Study preserves hopes for Roche’s Tecentriq in lung cancer

A clinical trial showed positive survival data for Swiss drugmaker Roche’s potential immunotherapy cocktail as an initial treatment for an aggressive form of lung cancer.

Read More »

GlaxoSmithKline Ends R&D Pact with OncoMed

OncoMed announced GlaxoSmithKline was terminating its nearly 10-year-old R&D agreement. OncoMed’s shares fell about 2 percent on the news.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom